CONTACT
+91 80 2808 2808
info@biocon.com
News-banner
Biocon  /  Biosimilar

Healthcare today

Reducing the health inequality

Over 2 billion people worldwide cannot afford life-saving medicines, which puts their lives at risk. Making potentially life-saving drugs more affordable and accessible can help patients live a prolonged and better quality of life as well as reduce the health inequality. Controlling drug expenditure could also be key to preventing future health care cost inflation, given the multiple challenges that burden the healthcare system worldwide due to an ageing and growing population, burgeoning middle class, complexities of cancer, diabetes, and other non-communicable diseases.

Biological medications are at the forefront of medical advances today but their formidable cost consumes a significant portion of public and private drug spending. In comparison, biosimilars (a highly similar version of biologics), offer an equally effective option at an affordable cost, which offers the promise of a more sustainable solution. Healthcare must take many forms and should be made accessible to people of all socio-economic backgrounds.

Making potentially life-saving drugs more affordable and accessible can help patients live a prolonged and better quality of life as well as reduce the health inequality.

Healthcare must take many forms and should be made accessible to people of all socio-economic backgrounds.

governance-footer-biocon

Understanding
Biologics

Transforming treatments for life-threatening illnesses

Biologic medicines contain substances that are made by living cells or organisms. They are usually made of proteins that are naturally produced in the human body.

governance-footer-biocon

Understanding
Biosimilars

Biocon giving patients a new lifeblood

Biosimilars are safe, effective and highly similar versions of approved and authorized biological medicines. They treat the same diseases as the reference biological medicine and with the same efficacy

Biocon Biosimilars

Achieving a sustainable health equity

Biocon Biologics is advancing a range of high-quality, safe and effective biosimilars that offer affordable solutions to expensive biologic medicines. Biosimilars offer the same quality as biologics but are affordable as their similarity to the reference drug structure, biological activity and efficacy, safety and immunogenicity profile, reduces their need for numerous clinical studies.

Biocon Biologics is strengthening its regulatory, commercial and manufacturing expertise to meet the demand for high quality biosimilars. As a key player in healthcare, we proactively seek innovative partnerships to offer patients, providers and payers an improved experience. Biosimilars facilitate greater patient access to affordable treatment and provide a viable path to cost reduction and quality improvement and offer a sustainable health equity.

legacy-footer-biocon

Biosimilars facilitate greater patient access to affordable treatment and provide a viable path to cost reduction and quality improvement and offer a sustainable
health equity.

Novel Biologics & Biosimilars

Products-banner

Biocon is a pioneer in bringing high quality, yet affordable, novel biologics & biosimilars to patients globally

Know more
about our
businesses

GENERICS »
BIOSIMILARS »
NOVEL BIOLOGICS »

about-us-footer-biocon
ABOUT US
functions-footer-biocon
KEY THERAPEUTIC AREAS
governance-footer-biocon
PRODUCT PIPELINE
partner-with-us-footer-biocon
PARTNER WITH US
legacy-footer-biocon
MANUFACTURING
Share
Previous Next
Close
Test Caption
Test Description goes like this